Ardeshir R Rastinehad
Overview
Explore the profile of Ardeshir R Rastinehad including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
101
Citations
2509
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Canfield S, George A, Jue J, Lewis S, Davenport M, Tammisetti V, et al.
J Urol
. 2025 Mar;
213(4):541.
PMID: 40052609
No abstract available.
2.
Rodriguez-Sanchez L, Cathelineau X, de Reijke T, Stricker P, Emberton M, Lantz A, et al.
BJU Int
. 2025 Feb;
PMID: 39905268
Objectives: To provide a contemporary statement on focal therapy (FT) for localised prostate cancer (PCa) from an international and diverse group of physicians treating localised PCa, with the aim of...
3.
Ghoreifi A, Hussain J, Tan W, Kenigsberg A, Gomella P, Yerram N, et al.
Eur Urol Focus
. 2025 Feb;
PMID: 39893046
No abstract available.
4.
5.
Ghoreifi A, Gomella L, Hu J, Konety B, Lunelli L, Rastinehad A, et al.
Prostate Cancer Prostatic Dis
. 2024 Oct;
PMID: 39443815
Background: Despite the evidence supporting the use of focal therapy (FT) in patients with localized prostate cancer (PCa), considerable variability exists in the patient selection criteria across current studies. This...
6.
Canfield S, George A, Jue J, Lewis S, Davenport M, Tammisetti V, et al.
J Urol
. 2024 Sep;
212(6):862-872.
PMID: 39226591
Purpose: Focal therapy aims to provide a durable oncologic treatment option for men with prostate cancer (PCa), while preserving their quality of life. Most focal therapy modalities rely on the...
7.
Kadria-Vili Y, Schwartz J, Polascik T, Goodrich G, Jorden D, Pinder D, et al.
Nanomaterials (Basel)
. 2024 Aug;
14(15).
PMID: 39120366
AuroLase Therapy-a nanoparticle-enabled focal therapy-has the potential to safely and effectively treat localized prostate cancer (PCa), preserving baseline functionality. This article presents a detailed case of localized PCa treated with...
8.
George A, Miocinovic R, Patel A, Lomas D, Correa A, Chen D, et al.
Cancers (Basel)
. 2024 Jun;
16(12).
PMID: 38927884
The PRESERVE study (NCT04972097) aims to evaluate the safety and effectiveness of the NanoKnife System to ablate prostate tissue in patients with intermediate-risk prostate cancer (PCa). The NanoKnife uses irreversible...
9.
Light A, Mayor N, Cullen E, Kirkham A, Padhani A, Arya M, et al.
Eur Urol
. 2024 Mar;
85(5):466-482.
PMID: 38519280
Background And Objective: Magnetic resonance imaging (MRI) can detect recurrences after focal therapy for prostate cancer but there is no robust guidance regarding its use. Our objective was to produce...
10.
Deivasigamani S, Kotamarti S, Rastinehad A, Salas R, de la Rosette J, Lepor H, et al.
Eur Urol
. 2023 Jul;
84(6):547-560.
PMID: 37419773
Context: Whole-gland ablation is a feasible and effective minimally invasive treatment for localized prostate cancer (PCa). Previous systematic reviews supported evidence for favorable functional outcomes, but oncological outcomes were inconclusive...